Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status

Aims Little is known about whether sodium intake is associated with the clinical effects of SGLT2 inhibitors (SGLT2is); however, SGLT2is may increase urinary sodium excretion. Thus, we investigated the impact of daily sodium intake on the estimated glomerular filtration rate (eGFR) via an SGLT2i, to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2019-07, Vol.21 (7), p.1715-1724
Hauptverfasser:	Nunoi, Kiyohide, Sato, Yuichi, Kaku, Kohei, Yoshida, Akihiro, Suganami, Hideki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Benzhydryl Compounds - adverse effects Benzhydryl Compounds - pharmacology Benzhydryl Compounds - therapeutic use Blood Glucose - drug effects Body mass index Clinical trials daily salt intake Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Dietary intake Epidermal growth factor receptors Excretion Female Glomerular filtration rate Glomerular Filtration Rate - drug effects Glucosides - adverse effects Glucosides - pharmacology Glucosides - therapeutic use Glycated Hemoglobin A - analysis Humans Male Middle Aged Original Patients Sodium Sodium, Dietary - analysis Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use sodium‐glucose cotransporter 2 inhibitor tofogliflozin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!